Intraoperative indocyanine green fluorescence imaging to predict early hepatic arterial complications after liver transplantation.


Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185

Informations de publication

Date de publication:
07 Mar 2024
Historique:
received: 09 11 2023
accepted: 19 02 2024
medline: 11 3 2024
pubmed: 11 3 2024
entrez: 11 3 2024
Statut: aheadofprint

Résumé

In liver transplantation (LT) setting, to propose an innovative intraoperative criterion to judge arterial flow abnormality that may lead to early hepatic arterial occlusion, i.e. thrombosis or stenosis, when left untreated and to carry out re-anastomosis. After liver graft implantation, and after ensuring that there is no abnormality on the Doppler ultrasound (qualitative and quantitative assessment), we intraoperatively injected indocyanine green dye (ICG, 0.01 mg/Kg) and we quantified the fluorescence signal at the graft pedicle using ImageJ software. From the obtained images of 89 adult patients transplanted in our center between September 2017 and April 2019, we constructed fluorescence intensity curves of the hepatic arterial signal, and examined their relationship with the occurrence of early hepatic arterial occlusion (thrombosis or stenosis). Early hepatic arterial occlusion occurred in seven patients (7.8%), including three thrombosis and four stenosis. Among various parameters of the flow intensity curve analyzed, the ratio of peak to plateau (RPP) fluorescence intensity and the jagged wave pattern at the plateau phase were closely associated with this dreaded event. By combining RPP at 0.275 and a jagged wave, we best predicted the occurrence of early hepatic arterial occlusion and thrombosis, with sensitivity/specificity of 0.86/0.98 and 1.00/0.94, respectively. Through a simple composite parameter, indocyanine green fluorescence imaging system is an additional and promising intraoperative modality for identifying transplant recipients at high risk of developing early hepatic arterial occlusion. This tool could assist the surgeon in the decision to redo the anastomosis despite normal Doppler ultrasonography.

Identifiants

pubmed: 38466885
doi: 10.1097/LVT.0000000000000355
pii: 01445473-990000000-00340
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Association for the Study of Liver Diseases.

Auteurs

Muga Terasawa (M)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.
Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.

Hiroshi Imamura (H)

Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.

Marc Antoine Allard (MA)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.
Inserm, Université Paris-Saclay, UMRS 1193, Physiopathogénèse et traitement des maladies du foie ; FHU Hepatinov, 94800, Villejuif, France.

Daniel Pietrasz (D)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.
Inserm, Université Paris-Saclay, UMRS 1193, Physiopathogénèse et traitement des maladies du foie ; FHU Hepatinov, 94800, Villejuif, France.

Oriana Ciacio (O)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.

Gabriella Pittau (G)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.

Chady Salloum (C)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.

Antonio Sa Cunha (A)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.
Inserm, Université Paris-Saclay, UMRS 1193, Physiopathogénèse et traitement des maladies du foie ; FHU Hepatinov, 94800, Villejuif, France.

Daniel Cherqui (D)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.
Inserm, Université Paris-Saclay, UMRS 1193, Physiopathogénèse et traitement des maladies du foie ; FHU Hepatinov, 94800, Villejuif, France.

René Adam (R)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.

Daniel Azoulay (D)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.
Inserm, Université Paris-Saclay, UMRS 1193, Physiopathogénèse et traitement des maladies du foie ; FHU Hepatinov, 94800, Villejuif, France.

Akio Saiura (A)

Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.

Eric Vibert (E)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.
Inserm, Université Paris-Saclay, UMRS 1193, Physiopathogénèse et traitement des maladies du foie ; FHU Hepatinov, 94800, Villejuif, France.

Nicolas Golse (N)

Hôpital Paul Brousse, Centre Hépato-Biliaire, AP-HP, Villejuif, France.
Inserm, Université Paris-Saclay, UMRS 1193, Physiopathogénèse et traitement des maladies du foie ; FHU Hepatinov, 94800, Villejuif, France.

Classifications MeSH